Zivo Bioscience Inc (ZIVO)

History and Background

Zivo Bioscience Inc. was founded in 2006. It focuses on developing nutritional and therapeutic products derived from algae. The company has evolved from an initial focus on biofuel to a focus on human and animal health applications.

Core Business Areas

• Human Health: Focuses on developing algal-derived products to support human health, specifically in areas like immune modulation and gut health.
• Animal Health: Developing feed additives and nutritional supplements for livestock, particularly poultry and dairy, to improve productivity and reduce reliance on antibiotics.

Leadership and Structure

Dr. John Payne is the CEO. The organizational structure includes teams dedicated to research and development, clinical trials, regulatory affairs, and business development.

Key Offerings

• DHAgA Oil: DHAgA Oil is the company's algae-based oil. It is used as a dietary supplement. Market share information is not readily available, but the product competes with fish oil and other algal oil suppliers like DSM and Corbion. This product is used in dietary supplements.
• Animal Feed Additives: ZIVO is working towards commercializing an algae-based feed additive for poultry. Market share and revenue figures are currently unavailable as the product is not yet fully commercialized. Competitors in the animal feed additives market include ADM, Cargill, and Novus International. This product is added to poultry feed as a nutrient source.

Industry Overview

The market for algae-based products is expanding, driven by increasing demand for sustainable and natural ingredients in food, supplements, and animal feed. The industry is characterized by innovation in algae cultivation and extraction technologies.

Positioning

Zivo Bioscience is positioned as an innovator in the algae-based nutraceutical and animal health markets. Its competitive advantage lies in its proprietary algae strain and extraction processes, enabling the development of unique products with potential health benefits.

Total Addressable Market (TAM)

The TAM for algae-based products spans multiple sectors, including human nutrition, animal feed, and pharmaceuticals, estimated at billions of dollars annually. Zivo Bioscience is positioned to capture a share of this market through its innovative products and strategic partnerships.

Key Competitors

• DSM (DSM.AS)
• Cargill (Private)
• ADM (ADM)

Competitive Landscape

Zivo Bioscience faces significant competition from larger, well-established companies. Its advantage lies in its novel algae strain and potential for differentiated products, but it needs to overcome challenges related to scale and commercialization.

Historical Growth: Historical growth has been limited, primarily focused on R&D progress.

Future Projections: Future growth is dependent on successful commercialization of its algal-based products. Analyst projections are highly speculative due to the company's stage of development.

Recent Initiatives: Recent strategic initiatives include ongoing clinical trials, partnerships with potential distributors, and efforts to secure regulatory approvals.

Zivo Bioscience is an early-stage company with promising technology but faces significant challenges related to funding, competition, and regulatory hurdles. The company's success depends on successful commercialization of its algal-based products and strategic partnerships. Ongoing R&D and clinical trials are critical for demonstrating the efficacy and safety of its products. Investors should be aware of the high-risk nature of investing in early-stage biotech companies.

Data Sources:

• Company Website
• SEC Filings
• Press Releases
• Third-party market research reports

Disclaimers:

This analysis is based on publicly available information and should not be considered investment advice. The information is subject to change without notice. Market share data is estimated.